Rivastigmine Tartrate
NDC Package 75834-135-05
Package Information
Rivastigmine Tartrate is capsules are contraindicated in patients with:known hypersensitivity to rivastigmine, other carbamate derivatives or other components of the formulation [see Description (11)].a previous history of application site reaction with rivastigmine transdermal patch suggestive of allergic contact dermatitis, in the absence of negative allergy testing [see Warnings and Precautions (5.2)].Isolated cases of generalized skin reactions have been described in postmarketing experience [see Adverse Reactions (6.2)]. Marketed by Nivagen Pharmaceuticals, Inc., this product is identified by NDC 75834-135 and is authorized under FDA application ANDA203844.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 75834 - Nivagen Pharmaceuticals, Inc.
- 75834-135 - Rivastigmine Tartrate
- 75834-135-05 - 500 CAPSULE in 1 BOTTLE, PLASTIC
- 75834-135 - Rivastigmine Tartrate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (75834-135). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 75834-135-05 identifies a specific commercial package of 500 capsule in 1 bottle, plastic of Rivastigmine Tartrate, labeled by Nivagen Pharmaceuticals, Inc.. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Nivagen Pharmaceuticals, Inc. on September 04, 2017. The current certification is valid through August 31, 2026.
How is this Nivagen Pharmaceuticals, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 75834013505. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 500 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.
